You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A new generation of targeted therapeutics for the treatment of cancer
SBC: NERX BIOSCIENCES, INC. Topic: NCIDESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: 102DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells
SBC: ZoneOne Pharma Topic: ODESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography
SBC: Vibronix, Inc. Topic: 102DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia
SBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Therapeutics to Treat Candida albicans Biofilm Infections
SBC: BIOSYNESIS, INC. Topic: NIAIDDESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus
SBC: ALTRAVAX, INC Topic: NIAIDDESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rapid Diagnostics for Mucormycosis
SBC: VITALEX BIOSCIENCES, LLC Topic: NIAIDDESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral Vector for the treatment of Fanconi Anemia
SBC: Rimedion, Inc. Topic: NHLBIDESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands
SBC: MATERIA, INC. Topic: 300DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health